The trouble began on July 14, 2026, when Celcuity confirmed FDA approval for the drug gedatolisib, marketed as Revtorpyk. While the approval itself was widely anticipated, the company’s guidance for a late third-quarter launch caught analysts off guard. Market experts at Stifel and Leerink both characterized the timeline as extended, noting that previous company commentary had signaled a higher degree of launch readiness than what was ultimately delivered.

Investors who incurred losses following the subsequent sell-off are now being encouraged to contact Kessler Topaz Meltzer & Check, LLP to review their legal rights. The firm, which maintains a significant track record in securities-fraud class actions, is currently assessing whether the company’s disclosures misled shareholders regarding the drug's path to market. There is no upfront cost for those seeking to discuss potential claims with the firm's legal team.